<version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource>
  <section secid="560" ordby="10" name="General">
    <field fieldid="11" ordby="20" id="561" name="Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Epilepsy: percentage of all patients with a diagnosis of epilepsy with active anti-seizure therapy side effects for whom an intervention was discussed.</div>"/>
    </field>
    <field fieldid="1" ordby="30" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Academy of Neurology. Epilepsy update: quality measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2014. 83 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="563" ordby="40" name="Measure Domain">
    <field fieldid="3025" ordby="50" id="564" name="Primary Measure Domain" type="picklist-one">
      <fieldvalue value="Clinical Quality Measures: Process"/>
    </field>
    <field fieldid="3026" ordby="60" id="565" name="Secondary Measure Domain" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
  </section>
  <section secid="566" ordby="70" name="Brief Abstract">
    <field fieldid="34" ordby="80" id="567" name="Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure is used to assess the percentage of all patients with a diagnosis of epilepsy with active anti-seizure therapy side effects for whom an intervention was discussed.</p></div>"/>
    </field>
    <field fieldid="21" ordby="90" id="568" name="Rationale" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Anti-seizure medications commonly cause neurological side effects such as sleepiness, dizziness, fatigue, and diplopia (Andrew et al., 2012). Some anti-seizure medications can cause idiosyncratic side effects such as weight changes, irritability or gastrointestinal issues. Patients must be queried about any general side effects and the side effects that accompany their specific therapy. Querying about side effects is perhaps the most straightforward, simple, and efficient intervention that could be provided to improve epilepsy care and patient engagement. Commonly these side effects can lead to decreased adherence thus increasing risk for further complications in epilepsy care.</p>
<p><strong>The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure</strong>:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>When a patient with epilepsy receives follow-up care, then an estimate of the number of seizures since the last visit and an assessment of drug side-effects should be documented (Pugh et al., 2007). </li>
    <li>Patients with epilepsy should receive an annual review of information including topics such as: chronic effects of epilepsy and its treatment including drug side-effects, drug-drug interactions, effect on bone health (Pugh et al., 2007). </li>
    <li>Children, young people and adults with epilepsy and their families and/or carers should be given, and have access to sources of, information about (where appropriate): &amp;hellip; medication and side effects (Andrew et al., 2012). </li>
    <li>Treatment should be reviewed at regular intervals to ensure that children, young people and adults with epilepsy are not maintained for long periods on treatment that is ineffective or poorly tolerated and that concordance with prescribed medication is maintained (National Institute for Health and Clinical Excellence [NICE], 2012). </li>
    <li>Annual review should include an enquiry about side effects and a discussion of the treatment plan to ensure concordance and adherence to medication (NICE, 2012). </li>
</ul>
<p><strong>Opportunity for Improvement</strong></p>
<p>A gap in care continues to exist with regard to querying about anti-seizure medication side effects as shown in some studies designed to determine the rate of compliance with the 2009 epilepsy quality measure (Fountain et al., 2011; Wicks &amp;amp; Fountain, 2012; Wasade et al., 2012; Cisneros-Franco et al., 2013; Fitzsimons et al., 2013). Using a standardized quality measure check list without any other intervention improved performance (Cisneros-Franco et al., 2013). Additionally, a recent review concluded, &quot;questioning every patient at every visit to elicit information may be helpful when balancing benefit-to-risk of individualized therapy during everyday practice&quot; (Cramer, 2012).</p>
<p>Further, if therapy adherence improves, there is a likelihood that costs of care would decrease, as anti-seizure medication nonadherence has been correlated with greater risk of hospital admissions, emergency department visits, head injuries, and fractures (Goodman et al., 2012).</p></div>"/>
    </field>
    <field fieldid="3500" ordby="100" id="569" name="Evidence for Rationale" type="citation">
      <fieldvalue value="<table><tr><td>American Academy of Neurology. Epilepsy update: quality measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2014. 83 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Andrew T, Milinis K, Baker G, Wieshmann U. Self reported adverse effects of mono and polytherapy for epilepsy. Seizure. 2012 Oct;21(8):610-3. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22795388&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Cisneros-Franco JM, Díaz-Torres MA, Rodríguez-Castañeda JB, Martínez-Silva A, Gutierrez-Herrera MA, San-Juan D. Impact of the implementation of the AAN epilepsy quality measures on the medical records in a university hospital. BMC Neurol. 2013;13:112. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23984949&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Cramer JA. Tolerability of antiepileptic drugs: can we determine differences?. Epilepsy Behav. 2012 Mar;23(3):187-92. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22366050&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Fitzsimons M, Dunleavy B, O'Byrne P, Dunne M, Grimson J, Kalra D, Normand C, Delanty N. Assessing the quality of epilepsy care with an electronic patient record. Seizure. 2013 Oct;22(8):604-10. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23537634&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT Jr, American Academy of Neurology Epilepsy Measure Development Panel and the American. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 4;76(1):94-9. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21205698&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Goodman MJ, Durkin M, Forlenza J, Ye X, Brixner DI. Assessing adherence-based quality measures in epilepsy. Int J Qual Health Care. 2012 Jun;24(3):293-300. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22507847&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>National Institute for Health and Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Jan. 117 p.&amp;nbsp;(Clinical guideline; no. 137).&amp;nbsp;</td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Pugh MJ, Berlowitz DR, Montouris G, Bokhour B, Cramer JA, Bohm V, Bollinger M, Helmers S, Ettinger A, Meador KJ, Fountain N, Boggs J, Tatum WO 4th, Knoefel J, Harden C, Mattson RH, Kazis L. What constitutes high quality of care for adults with epilepsy. Neurology. 2007 Nov 20;69(21):2020-7. [40 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17928576&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Wasade VS, Spanaki M, Iyengar R, Barkley GL, Schultz L. AAN Epilepsy Quality Measures in clinical practice: a survey of neurologists. Epilepsy Behav. 2012 Aug;24(4):468-73. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22770880&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Wicks P, Fountain NB. Patient assessment of physician performance of epilepsy quality-of-care measures. Neurol Clin Pract. 2012 Dec;2(4):335-42. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23634376&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3022" ordby="110" id="570" name="Primary Health Components" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Epilepsy; anti-seizure therapy side effects; intervention</p></div>"/>
    </field>
    <field fieldid="23" ordby="120" id="571" name="Denominator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>All visits for patients with a diagnosis of epilepsy actively receiving anti-seizure therapy with a side effect noted at time of visit (see the related &quot;Denominator Inclusions/Exclusions&quot; field)</p></div>"/>
    </field>
    <field fieldid="24" ordby="130" id="572" name="Numerator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients with anti-seizure therapy side effects for whom an intervention was discussed (see the related &quot;Numerator Inclusions/Exclusions&quot; field)</p></div>"/>
    </field>
  </section>
  <section secid="573" ordby="140" name="Evidence Supporting the Measure">
    <field fieldid="3027" ordby="150" id="574" name="Type of Evidence Supporting the Criterion of Quality for the Measure" type="picklist-choice">
      <fieldvalue value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence"/>
      <fieldvalue value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences"/>
      <fieldvalue value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal"/>
    </field>
    <field fieldid="3501" ordby="160" id="575" name="Additional Information Supporting Need for the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Importance of Topic</strong></p>
<p>Epilepsy data is lacking. In 2012, the Institute of Medicine released <em>Epilepsy across the Spectrum: Promoting Health and Understanding</em>, detailing epilepsy research disparities and highlighting specific areas where further research is needed, including the extent of epilepsy, consequences, comorbid conditions and outcomes of epilepsy (England et al., 2012). The following statistics only touch on the magnitude of epilepsy given lack of research and stigma: </p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>It is estimated 2.2 million people in the United States are diagnosed with epilepsy, and 150,000 new cases of epilepsy are diagnosed in the United States annually (England et al., 2012). </li>
    <li>Epilepsy prevalence might be underestimated because of underreporting associated with repercussions and stigma in disclosing epilepsy (Kobau et al., 2012). </li>
    <li>Common comorbidities among people with epilepsy include somatic (i.e., fractures, asthma, diabetes, and heart disease), neurological (i.e., stroke, Alzheimer's disease, autism spectrum disorders, chronic pain), and mental health conditions (i.e., mood disorders, attention deficit hyperactivity disorders, anxiety disorders, suicidality) (England et al., 2012; Kobau et al., 2008). </li>
    <li>It is estimated the number of people with epilepsy who die of sudden unexpected death in epilepsy (SUDEP) range from 1 of every 10,000 who are newly diagnosed to 9 of every 1,000 candidates for epilepsy surgery (England et al., 2012). </li>
    <li>People with epilepsy are more likely to be unemployed or unable to work, have low annual household incomes, be obese and physically inactive, and to smoke (England et al., 2012; Kobau et al., 2008). </li>
    <li>People with epilepsy have poorer overall health status, impaired intellectual and physical functioning, a greater risk for accidents and injuries, and negative side effects from seizure medications (Fountain et al., 2011; England et al., 2012; Kobau et al., 2008). </li>
    <li>It is estimated the annual direct medical cost of epilepsy in the United States is $9.6 billion. This estimate does not include community service costs or indirect costs from losses in quality of life and productivity (England et al., 2012). </li>
</ul>
<p><strong>Opportunities for Improvement</strong></p>
<p>Additional data on opportunities for improvement and gaps in care specific to the epilepsy measures can be located in the updated epilepsy measures. </p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>A review of 261 patient responses using the PatientsLikeMe survey system indicated a gap remains between recommended care detailed in the 2009 epilepsy measurement set and the care delivered to patients with epilepsy (Wicks &amp;amp; Fountain, 2012). </li>
    <li>The Institute of Medicine noted several gaps in care and opportunities for improvement, including 1) timely referrals and access to treatments, 2) epilepsy care and prevention, 3) education of persons with epilepsy and their families, and 4) the stigma of epilepsy (England et al., 2012). </li>
    <li>Surgery continues to be heavily underutilized as a treatment for epilepsy, with significant disparities by race and insurance coverage (Englot et al., 2012). </li>
</ul></div>"/>
    </field>
    <field fieldid="3502" ordby="170" id="576" name="Evidence for Additional Information Supporting Need for the Measure" type="citation">
      <fieldvalue value="<table><tr><td>American Academy of Neurology. Epilepsy update: quality measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2014. 83 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>England MJ, Liverman CT, Schultz AM, Strawbridge LM. Epilepsy across the spectrum: promoting health and understanding. 1st ed. Washington (DC): The National Academies Press; 2012. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Englot DJ, Ouyang D, Garcia PA, Barbaro NM, Chang EF. Epilepsy surgery trends in the United States, 1990-2008. Neurology. 2012 Apr 17;78(16):1200-6. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22442428&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT Jr, American Academy of Neurology Epilepsy Measure Development Panel and the American. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 4;76(1):94-9. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21205698&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Kobau R, Luo YH, Zack MM, et al. Epilepsy in adults and access to care--United States, 2010. MMWR Morb Mortal Wkly Rep. 2012 Nov 16;61(45):909-13. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23151949&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Kobau R, Zahran H, Thurman DJ, Zack MM, Henry TR, Schachter SC, Price PH, Centers for Disease Control and Prevention (CDC). Epilepsy surveillance among adults--19 States, Behavioral Risk Factor Surveillance System, 2005. Morb Mortal Wkly Rep Surveill Summ. 2008 Aug 8;57(6):1-20. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18685554&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Wicks P, Fountain NB. Patient assessment of physician performance of epilepsy quality-of-care measures. Neurol Clin Pract. 2012 Dec;2(4):335-42. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23634376&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3072" ordby="180" id="577" name="Extent of Measure Testing" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The new epilepsy measures are being made available without any prior testing. The American Academy of Neurology encourages testing of this measurement set for feasibility and reliability by organizations or individuals positioned to do so. </p></div>"/>
    </field>
    <field fieldid="3007" ordby="190" id="578" name="Evidence for Extent of Measure Testing" type="citation">
      <fieldvalue value="<table><tr><td>American Academy of Neurology. Epilepsy update: quality measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2014. 83 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="580" ordby="210" name="State of Use of the Measure">
    <field fieldid="3029" ordby="220" id="581" name="State of Use" type="picklist-one">
      <fieldvalue value="Current routine use"/>
    </field>
    <field fieldid="3030" ordby="230" id="582" name="Current Use" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="583" ordby="240" name="Application of the Measure in its Current Use">
    <field fieldid="3031" ordby="250" id="584" name="Measurement Setting" type="picklist-choice">
      <fieldvalue value="Ambulatory/Office-based Care"/>
      <fieldvalue value="Hospital Inpatient"/>
    </field>
    <field fieldid="3032" ordby="260" id="585" name="Professionals Involved in Delivery of Health Services" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3033" ordby="270" id="586" name="Least Aggregated Level of Services Delivery Addressed" type="picklist-one">
      <fieldvalue value="Individual Clinicians or Public Health Professionals"/>
    </field>
    <field fieldid="3505" ordby="280" id="587" name="Statement of Acceptable Minimum Sample Size" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="41" ordby="290" id="588" name="Target Population Age" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="42" ordby="300" id="589" name="Target Population Gender" type="picklist-one">
      <fieldvalue value="Either male or female"/>
    </field>
  </section>
  <section secid="660" ordby="310" name="National Strategy for Quality Improvement in Health Care">
    <field fieldid="3522" ordby="320" id="661" name="National Quality Strategy Aim" type="text">
      <fieldvalue value="<ul><li>Better Care</li></ul>"/>
    </field>
    <field fieldid="3525" ordby="330" id="662" name="National Quality Strategy Priority" type="text">
      <fieldvalue value="<ul><li>Person- and Family-centered Care</li><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>"/>
    </field>
  </section>
  <section secid="590" ordby="340" name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <field fieldid="3163" ordby="350" id="591" name="IOM Care Need" type="picklist-choice">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="3164" ordby="360" id="592" name="IOM Domain" type="picklist-choice">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="593" ordby="370" name="Data Collection for the Measure">
    <field fieldid="3506" ordby="380" id="594" name="Case Finding Period" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3054" ordby="390" id="595" name="Denominator Sampling Frame" type="picklist-one">
      <fieldvalue value="Patients associated with provider"/>
    </field>
    <field fieldid="3057" ordby="400" id="598" name="Denominator (Index) Event or Characteristic" type="picklist-choice">
      <fieldvalue value="Clinical Condition"/>
      <fieldvalue value="Encounter"/>
      <fieldvalue value="Therapeutic Intervention"/>
    </field>
    <field fieldid="3058" ordby="410" id="599" name="Denominator Time Window" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="55" ordby="420" id="596" name="Denominator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
All visits for patients with a diagnosis of epilepsy actively receiving anti-seizure therapy with a side effect noted at time of visit</p>
<p class=&quot;Note&quot;><strong>Note</strong>: Refer to the original measure documentation for International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), and Current Procedural Terminology (CPT) Evaluation and Management (E/M) service codes. </p>
<p><strong>Exclusions</strong><br />
Unspecified</p>
<p><strong>Exceptions</strong><br />
Patient or caregiver declines to answer questions on anti-seizure medication side effects.</p></div>"/>
    </field>
    <field fieldid="3507" ordby="430" id="597" name="Exclusions/Exceptions" type="picklist-choice-4">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="59" ordby="440" id="600" name="Numerator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
Patients with anti-seizure therapy side effects for whom an intervention* was discussed</p>
<p class=&quot;Note&quot;>*<em>Intervention</em>: Discussion about significance of side effect symptom and consideration of adjustment in anti-seizure therapy or medication dose or providing alleviating treatment.</p>
<p><strong>Exclusions</strong><br />
Unspecified</p></div>"/>
    </field>
    <field fieldid="3061" ordby="450" id="601" name="Numerator Search Strategy" type="picklist-one">
      <fieldvalue value="Fixed time period or point in time"/>
    </field>
    <field fieldid="3062" ordby="460" id="602" name="Data Source" type="picklist-many">
      <fieldvalue value="Electronic health/medical record"/>
    </field>
    <field fieldid="3065" ordby="470" id="603" name="Type of Health State" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3066" ordby="480" id="604" name="Instruments Used and/or Associated with the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
  </section>
  <section secid="605" ordby="490" name="Computation of the Measure">
    <field fieldid="3508" ordby="500" id="606" name="Measure Specifies Disaggregation" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3067" ordby="520" id="608" name="Scoring" type="picklist-many">
      <fieldvalue value="Rate/Proportion"/>
    </field>
    <field fieldid="3068" ordby="530" id="609" name="Interpretation of Score" type="picklist-one">
      <fieldvalue value="Desired value is a higher score"/>
    </field>
    <field fieldid="3090" ordby="540" id="610" name="Allowance for Patient or Population Factors" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3070" ordby="560" id="612" name="Standard of Comparison" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="615" ordby="590" name="Identifying Information">
    <field fieldid="73" ordby="600" id="616" name="Original Title" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Measure #3: querying and intervention for side effects of anti-seizure therapy.</p></div>"/>
    </field>
    <field fieldid="74" ordby="610" id="617" name="Measure Collection Name" type="text">
      <fieldvalue value="Epilepsy Quality Measurement Set"/>
    </field>
    <field fieldid="16" ordby="650" id="621" name="Submitter" type="orglist">
      <fieldvalue value="American Academy of Neurology - Medical Specialty Society"/>
    </field>
    <field fieldid="17" ordby="660" id="622" name="Developer" type="orglist-p">
      <fieldvalue value="American Academy of Neurology - Medical Specialty Society"/>
    </field>
    <field fieldid="79" ordby="670" id="623" name="Funding Source(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Academy of Neurology</p></div>"/>
    </field>
    <field fieldid="80" ordby="680" id="624" name="Composition of the Group that Developed the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Epilepsy 2014 Update Work Group Members</strong></p>
<p><em>Co-Chairs</em>: Nathan Fountain, MD; Paul C. Van Ness, MD</p>
<p><em>American Academy of Neurology</em>: Jerome Engel, Jr., MD, PhD, FAAN; David S. Gloss, MD; Christiane Heck, MD, MMM; Diego A. Morita, MD; Marianna V. Spanaki, MD, PhD, MBA; Thaddeus Walczak, MD </p>
<p><em>American Academy of Family Physicians</em>: Mark C. Potter, MD </p>
<p><em>American Academy of Pediatrics</em>: Edwin Trevathan, MD, MPH </p>
<p><em>American Association of Neurological Surgeons/Congress of Neurosurgeons</em>: Joseph Neimat, MD </p>
<p><em>American Association of Neuroscience Nurses</em>: Mona Stecker, DNP, NP-BC, CNRN, SCRN </p>
<p><em>American Board of Internal Medicine</em>: Sharon M. Hibay, RN, DNP </p>
<p><em>American Clinical Neurophysiology Society</em>: Susan T. Herman, MD </p>
<p><em>American College of Emergency Physicians</em>: J. Stephen Huff, MD </p>
<p><em>American Epilepsy Society</em>: Gabriel U. Martz, MD </p>
<p><em>American Society of Neuroradiology/American College of Radiology</em>: Marvin Nelson, MD </p>
<p><em>Child Neurology Society</em>: Inna Hughes, MD, PhD </p>
<p><em>Citizens United for Research in Epilepsy</em>: Tracy Dixon-Salazar, PhD</p>
<p><em>Epilepsy Foundation</em>: Janice M. Buelow, RN, PhD </p>
<p><em>National Academy of Neuropsychology</em>: Daniel Drane, PhD, ABPP(CN)</p>
<p><em>National Association of Epilepsy Centers</em>: Ramon Bautista, MD, MBA </p>
<p><em>OptumInsight</em>: Kay Schwebke, MD, MPH, MA </p>
<p><em>Veterans Affairs Epilepsy Centers of Excellence</em>: Karen Parko, MD, FAAN </p>
<p><em>Independent Representatives</em>: Laurie A. Olmon; Mary Jo Pugh, PhD, RN </p>
<p><em>Work Group Facilitators</em>: John R. Absher, MD, FAAN; Anup D. Patel, MD; Kevin N. Sheth, MD, FAHA, FCCM, FNCS </p>
<p><em>American Academy of Neurology Staff</em>: Amy Bennett, JD; Gina Gjorvad; Becky Schierman, MPH; Rebecca J. Swain-Eng, MS, CAE </p></div>"/>
    </field>
    <field fieldid="81" ordby="690" id="625" name="Financial Disclosures/Other Potential Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="82" ordby="700" id="626" name="Endorser" type="orglist">
      <fieldvalue value="American Epilepsy Society - Medical Specialty Society"/>
      <fieldvalue value="Child Neurology Society - Medical Specialty Society"/>
      <fieldvalue value="Epilepsy Foundation - Medical Specialty Society"/>
    </field>
    <field fieldid="3510" ordby="710" id="627" name="Date of Endorsement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Epilepsy Society: 2013 Jul 29<br />
Child Neurology Society: 2014 Jul 29<br />
Epilepsy Foundation: 2014 Aug 7</p></div>"/>
    </field>
    <field fieldid="19" ordby="730" id="629" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="3086" ordby="740" id="630" name="Date of Most Current Version in NQMC" type="date">
      <fieldvalue value="2014 Jan"/>
    </field>
    <field fieldid="3511" ordby="750" id="631" name="Measure Maintenance" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3512" ordby="760" id="632" name="Date of Next Anticipated Revision" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="20" ordby="770" id="633" name="Measure Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the measure.</p></div>"/>
    </field>
    <field fieldid="14" ordby="780" id="634" name="Measure Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Source available from the <a href=&quot;https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/2.Quality_Improvement/1.Quality_Measures/1.All_Measures/2014%2009%2001%20Epilepsy%20Update%20Final.pdf&quot; title=&quot;AAN Web site&quot;>American Academy of Neurology (AAN) Web site</a>.</p>
<p>For more information, contact AAN at 201 Chicago Avenue, Minneapolis, MN 55415; Phone: 800-879-1960; Fax: 612-454-2746; Web site: <a href=&quot;http://www.aan.com&quot; title=&quot;AAN Web site&quot;>www.aan.com</a>.</p></div>"/>
    </field>
    <field fieldid="87" ordby="800" id="636" name="NQMC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary was completed by ECRI Institute on January 6, 2016. The information was not verified by the measure developer. </p></div>"/>
    </field>
    <field fieldid="88" ordby="810" id="637" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="641" ordby="850" name="Production">
    <field fieldid="1" ordby="1366" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Academy of Neurology. Epilepsy update: quality measurement set. St. Paul (MN): American Academy of Neurology (AAN); 2014. 83 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NQMC Disclaimer" type="text">
      <fieldvalue value="<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 01:52:00 Jul 06, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 22:37:06 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 1328.594 (3)
  esindex: 0.012
  captures_list: 1360.786
  CDXLines.iter: 21.493 (3)
  PetaboxLoader3.datanode: 119.974 (4)
  exclusion.robots: 0.305
  exclusion.robots.policy: 0.285
  RedisCDXSource: 3.96
  PetaboxLoader3.resolve: 2109.349 (3)
  load_resource: 1330.713
-->